Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.

Neurocrine Biosciences Inc. announced today that the U.S. Food and Drug Administration approved an 80-mg Ingrezza (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia.

Astellas Pharma struck a deal valued at up to $853 million to acquire Belgium-based Ogeda SA, a privately held clinical-stage drug discovery company, and its lead drug candidate fezolinetant.